Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial

BACKGROUND: Extending the duration of adjuvant endocrine therapy reduces the risk of recurrence in a subset of women with early-stage hormone receptor-positive (HR+) breast cancer. Validated predictive biomarkers of endocrine response could significantly improve patient selection for extended therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartlett, J M S, Sgroi, D C, Treuner, K, Zhang, Y, Ahmed, I, Piper, T, Salunga, R, Brachtel, E F, Pirrie, S J, Schnabel, C A, Rea, D W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927322/
https://www.ncbi.nlm.nih.gov/pubmed/31504126
http://dx.doi.org/10.1093/annonc/mdz289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927322/
https://www.ncbi.nlm.nih.gov/pubmed/31504126
http://dx.doi.org/10.1093/annonc/mdz289

Ejemplares similares